Full Press Release Details
Inc. to Report First Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, May 5
Management to host conference call at 4:30 pm ET on that day
JOLLA, Calif, April 28, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the "Company" or "INmune"),
a clinical- stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease,
today announced that it will host a conference call on Wednesday, May 5, 2021 at 4:30 PM Eastern Time to discuss results for its first
quarter ended March 31, 2021 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching an operator.
Time: 4:30 PM Eastern Time Participant Dial-in: 1-877-407-0784
Participant Dial-in (international): 1-201-689-8560
A transcript will follow approximately 24 hours from the
scheduled call. A replay will also be available through Wednesday, May 12, 2021 by dialing 1-844-512-2921 or 1-412-317-6671 (international)
and entering PIN no. 13718747.
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded
(NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.
INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant- negative technology to selectively neutralize soluble
TNF, a key driver of innate immune dysfunction and mechanistic target of many diseases. DN-TNF is currently being developed for COVID-19
complications (Quellor ), cancer (INB03 ), Alzheimer's (XPro595), and NASH (LIVNate ). The Natural Killer Cell
Priming Platform includes INKmune aimed at priming the patient's NK cells to eliminate minimal residual disease in patients
with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please visit www.inmunebio.com.
Bio Contact: David Moss, CFO (858) 964-3720
LifeSci Advisors, LLC (917) 741-7792